Practice Signal

Deprescribing Works on Paper. Does It Change Outcomes?

Geriatrics / Polypharmacy 7 sources · Updated Aug 17, 2026

This review helps pharmacists judge which deprescribing strategies reliably cut inappropriate medications, where they translate to clinical outcomes, and how to operationalize the how of stopping a drug.

Bottom Line

Pharmacist-led medication review and embedded decision-support algorithms reliably reduce inappropriate prescribing in older adults, and newer transition-of-care and N-of-1 approaches are beginning to link deprescribing to hard outcomes like readmission, but consistent downstream mortality or symptom benefit remains unproven.

0.84

adjusted HR, readmission or ED visit

74.2%

elders on an anticholinergic

36.7%

no tamsulosin benefit over placebo

Class I

minimize anticholinergics, Beers

State of Play

Structured deprescribing consistently reduces potentially inappropriate medication (PIM) burden in older adults, with pharmacist-led review and embedded electronic algorithms the most dependable strategies. The harder question, whether reducing pills changes hospitalizations, agitation, or mortality, remains only partially answered, and effect on hard endpoints is inconsistent across settings.

What Changed

The 2023 American Geriatrics Society (AGS) Beers Criteria expanded proton pump inhibitor (PPI) and anticholinergic guidance and added tramadol, meclizine, and glucagon-like peptide-1 (GLP-1) receptor agonist monitoring, while a Korean hospital polypharmacy program (PMID 42570168) newly tied reconciliation-based deprescribing to lower 90-day readmissions. N-of-1 tamsulosin trials (PMID 42406401) and qualitative implementability work (PMID 42573882) shifted the conversation from whether to deprescribe toward how to do it at the individual and guideline level.

How It Fits the Guidelines

The Beers Criteria and Screening Tool of Older Persons' Prescriptions/Screening Tool to Alert to Right Treatment (STOPP/START) frameworks identify what to stop but, as clinicians reported, give limited operational detail on tapering, monitoring, and co-interventions. The synthesis evidence largely reinforces these frameworks while exposing the gap the guidelines have not yet closed: named targets without an actionable how, and scale disagreement that undermines consistent anticholinergic scoring.

Evidence at a Glance

Source	Key finding	Grade / Verdict
Pharmacist-Led Reviews and Automated Algorithms Cut Inappropriate Medications Study · Geriatrics & Gerontology International core efficacy evidence Establishes pharmacist-led review and embedded algorithms as the most reliable PIM-reduction strategies in primary care, with physician-only review insufficient.	Pharmacist-led review reduced PIMs per patient, mean difference -0.43 (95% CI -0.54 to -0.32)	Grade: Moderate Confirmatory
Korea's Hospital Polypharmacy Program Cuts 90-Day Readmissions in Elders Study · Drugs & Aging outcomes bridge Links inpatient reconciliation-based deprescribing to lower 90-day readmissions and a strong benefit-cost ratio, moving beyond process measures.	Composite readmission or ED visit reduced, adjusted hazard ratio 0.84 (95% CI 0.74-0.95)	Grade: Moderate Confirmatory
Integrated Care Pathway Cuts Early Polypharmacy But Not Agitation Study · Alzheimer's & Dementia : the Journal of the Alzheimer's Association negative or null signal Shows a structured dementia pathway matched usual care on agitation and only transiently reduced psychotropic polypharmacy, tempering enthusiasm for formal algorithms in well-resourced settings.	Week-12 inpatient polypharmacy 53% in pathway arm versus 70% usual care, but no durable significant separation	Grade: Moderate Inconclusive
Anticholinergic Exposure Reaches 74% in Community-Dwelling Elders, Scales Disagree Study · Frontiers in Pharmacology measurement caveat Demonstrates that anticholinergic burden is highly prevalent, benzodiazepine-driven, and heavily dependent on which scale is used.	Anticholinergic exposure 74.2% overall, but scale-specific prevalence ranged from 14.8% (ARS) to 60.5% (ADS)	Grade: Moderate Confirmatory
How Clinicians Want Deprescribing Written Into Practice Guidelines Study · Journal of General Internal Medicine implementation gap Maps why clinicians find deprescribing guidance unusable and distills seven implementability principles centered on specifying the operational how.	Narrative guideline, no single statistic	Grade: Low Hypothesis-generating
N-of-1 Trials Reveal One-Third of Older Men Gain No Tamsulosin Benefit Study · JAMA Network Open individualized method Proves N-of-1 discontinuation trials are feasible and that group-average efficacy conceals a large nonresponder subgroup.	36.7% of older men on chronic tamsulosin had minimal or no benefit over placebo	Grade: Low Hypothesis-generating
Key Changes in 2023 AGS Beers Criteria for Inappropriate Medications in Older Adults Guideline · J Am Geriatr Soc guideline backbone Provides the updated AGS Beers Criteria framework naming PPIs, anticholinergics, tramadol, and hypnotics as priority deprescribing targets.	Minimize anticholinergic burden and hypnotics including Z-drugs, both Class I, Level A	Grade: Moderate Practice-changing

Practice Considerations

Position pharmacist-led medication review as a core geriatric service rather than an adjunct, since it reduced PIMs where physician-only review did not, and pair it with embedded decision-support algorithms (such as PRIMA-eDS or STOPP/START-based electronic tools) where staffing is limited.
Build reconciliation-based deprescribing into every transition-of-care workflow for high-risk older adults, since inpatient reconciliation was associated with lower 90-day readmissions but not fewer emergency department visits, arguing for post-discharge and community pharmacy follow-up.
Prioritize benzodiazepine review in anticholinergic burden reduction, since benzodiazepines, not classic agents like oxybutynin or amitriptyline, were the dominant driver of cumulative exposure, and select one scale and apply it consistently given up to fourfold disagreement between instruments.
Consider structured, symptom-tracked discontinuation trials rather than assuming lifelong therapy for drugs with heterogeneous individual benefit, using tamsulosin as the model where roughly one-third of chronic users gained no benefit over placebo and patient satisfaction was unreliable.
When authoring or advocating for deprescribing protocols, specify the operational how, meaning explicit taper schedules, monitoring parameters, and co-interventions, and define ambiguous verbs like taper and withdraw to prevent abrupt cessation.
Frame deprescribing to prescribers as low risk, since no included trial demonstrated increased mortality or harm from careful medication reduction, while setting realistic expectations that formal pathways may add little in well-resourced academic units.

Open Questions

Does reducing PIM burden translate into consistent reductions in mortality, falls, or cognitive decline, or does benefit stop at process measures and readmission?
Which anticholinergic burden scale best predicts clinical harm, given weak inter-scale agreement and no head-to-head outcome comparison?
Can N-of-1 discontinuation trials be scaled beyond self-selected populations, and do they establish long-term safety and identify response predictors?
What guideline wording, placement, and format actually increase deprescribing rates at the point of care, since the implementability principles were not tested against outcomes?

deprescribing polypharmacy proton pump inhibitors benzodiazepines opioids tramadol anticholinergics tamsulosin alpha-1 blockers antihyperglycemics GLP-1 receptor agonists geriatrics

🎓

Synthesized and reviewed by a licensed pharmacist

Each Practice Signal is built from our published deep analyses and checked for clinical accuracy before it goes live.

Not medical advice. PharmD Signal provides educational synthesis of published pharmacy and medical literature for practicing pharmacists. It is not a treatment recommendation for any individual patient; clinical decisions remain the responsibility of the treating clinician exercising independent professional judgment.

Thanks for the feedback!

← Back to Evidence Rounds